

Citations

1. Garlid KD, Paucek P. The mitochondrial potassium cycle. *IUBMB Life* 2001;52:153-158.
2. Wahr JA, Parks R, Boisvert D et al. Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. Multicenter Study of Perioperative Ischemia Research Group. *JAMA* 1999;281:2203-2210.
3. Davis DR, Epp MD, Riordan HD. Changes in USDA food composition data for 43 garden crops, 1950 to 1999. *J Am Coll Nutr* 2004;23:669-682.
4. Lemann J Jr, Pleuss JA, Gray RW, Hoffmann RG. Potassium administration reduces and potassium deprivation increases urinary calcium excretion in healthy adults [corrected]. *Kidney Int* 1991;39:973-983.
5. Sakhaee K, Alpern R, Jacobson HR, Pak CY. Contrasting effects of various potassium salts on renal citrate excretion. *J Clin Endocrinol Metab* 1991;72:396-400.
6. Panel on Dietary Reference Intakes for Electrolytes and Water, Food and Nutrition Board, US Institute of Medicine. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. Washington, DC: National Academy Press; 2004:173-246.
7. Teh MM, Zaman MJ, Brooks AP, Li Voon Chong JS. When is a high potassium not a high potassium? *J R Soc Med* 2003;96:354-355.
8. Spector SL. Adverse reactions associated with parenteral beta agonists: serum potassium changes. *N Engl Reg Allergy Proc* 1987;8:317-321.
9. Phillips PJ, Vedig AE, Jones PL et al. Metabolic and cardiovascular side effects of the beta 2-adrenoceptor agonists salbutamol and rimiterol. *Br J Clin Pharmacol* 1980;9:483-491.
10. Edner M, Jogestrand T. Oral salbutamol decreases serum digoxin concentration. *Eur J Clin Pharmacol* 1990;38:195-197.
11. Ramsay LE, Hettiarachchi J, Fraser R, Morton JJ. Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients. *Clin Pharmacol Ther* 1980;27:533-543.
12. Chiu TF, Bullard MJ, Chen JC et al. Rapid life-threatening hyperkalemia after addition of amiloride HCl/hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy. *Ann Emerg Med* 1997;30:612-615.
13. Barr GA, Mazze RI, Cousins MJ, Kosek JC. An animal model for combined methoxyflurane and gentamicin nephrotoxicity. *Br J Anaesth* 1973;45:306-312.
14. Mazze RI, Cousins MJ. Combined nephrotoxicity of gentamicin and methoxyflurane anaesthesia in man: a case report. *Br J Anaesth* 1973;45:394-398.
15. Kes P, Reiner Z. Symptomatic hypomagnesemia associated with gentamicin therapy. *Magn Trace Elem* 1990;9:54-60.
16. Valdivieso A, Mardones JM, Loyola MS, Cubillos AM. [Hypomagnesemia associated with hypokalemia, hyponatremia and metabolic alkalosis: possible complication of gentamicin therapy]. *Rev Med Chil* 1992;120:914-919.
17. Parsons PP, Garland HO, Harpur ES, Old S. Acute gentamicin-induced hypercalciuria and hypermagnesiuria in the rat: dose-response relationship and role of renal tubular injury. *Br J Pharmacol* 1997;122:570-576.
18. Barton CH, Pahl M, Vaziri ND, Cesario T. Renal magnesium wasting associated with amphotericin B therapy. *Am J Med* 1984;77:471-474.
19. British National Formulary (BNF 52); London: BMJ Publishing Group and RPS Publishing; 2006.
20. Bernardo JF, Murakami S, Branch RA, Sabra R. Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules. *Nephron* 1995;70:235-241.
21. Utz JP. Amphotericin B toxicity: general side effects. *Ann Intern Med* 1964;61:340-343.
22. Butler WT, Hill GJ 2nd, Szwed CF, Knight V. Amphotericin B renal toxicity in the dog. *J Pharmacol Exp Ther* 1964;143:47-56.
23. Butler WT, Hill GJ 2nd. Intravenous administration of amphotericin B in the dog. *J Am Vet Med Assoc* 1964;144:399-402.
24. Butler WT, Bennett JE, Hill GJ 2nd. Electrocardiographic and electrolyte abnormalities caused by amphotericin B in dog and man. *Proc Soc Exp Biol Med* 1964;116:857-863.
25. Butler WT, Bennett JE, Alling DW et al. Nephrotoxicity of amphotericin B: early and late effects in 81 patients. *Ann Intern Med* 1964;61:175-187.
26. Butler WT. Amphotericin B toxicity: changes in renal function. *Ann Intern Med* 1964;61:344-349.
27. Craven PC, Gremillion DH. Risk factors of ventricular fibrillation during rapid amphotericin B infusion. *Antimicrob Agents Chemother* 1985;27:868-871.
28. Wazny LD, Brophy DF. Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia. *Ann Pharmacother* 2000;34:94-97.
29. Smith SR, Galloway MJ, Reilly JT, Davies JM. Amiloride prevents amphotericin B related hypokalaemia in neutropenic patients. *J Clin Pathol* 1988;41:494-497.
30. Bearden DT, Muncey LA. The effect of amiloride on amphotericin B-induced hypokalaemia. *J Antimicrob Chemother* 2001;48:109-111.

Citations and Reference Literature: Potassium

31. Pasic S, Flannagan L, Cant AJ. Liposomal amphotericin (AmBisome) is safe in bone marrow transplantation for primary immunodeficiency. *Bone Marrow Transplant* 1997;19:1229-1232.
32. Da Silva PS, de Oliveira Iglesias SB, Waisberg J. Hypokalemic rhabdomyolysis in a child due to amphotericin B therapy. *Eur J Pediatr* 2007;166(2):169-171.
33. Rado JP. Prediction of hyperkalemia associated with prolonged treatment with captopril by glucose-induced acute serum potassium changes. *Exp Clin Endocrinol* 1984;84:143-147.
34. Rush JE, Merrill DD. The safety and tolerability of lisinopril in clinical trials. *J Cardiovasc Pharmacol* 1987;9 Suppl 3:S99-S107.
35. Good CB, McDermott L, McCloskey B. Diet and serum potassium in patients on ACE inhibitors. *JAMA* 1995;274:538.
36. O'Keefe S, Grimes H, Finn J et al. Effect of captopril therapy on lymphocyte potassium and magnesium concentrations in patients with congestive heart failure. *Cardiology* 1992;80:100-105.
37. Lavin F, O'Keefe S, Grimes H et al. Effect of prolonged nifedipine or captopril therapy on lymphocyte magnesium and potassium levels in hypertension. *Cardiology* 1993;82:405-408.
38. Sifton DW et al. Physicians' Desk Reference. Montvale, NJ: Medical Economics Company; 2000:1965-1968.
39. Ohya Y, Ueno M, Takata Y et al. Crossover comparison of the effects of enalapril and captopril on potassium homeostasis in patients with mild hypertension. *Int J Clin Pharmacol Ther* 1994;32:655-659.
40. Stoltz ML, Andrews CE Jr. Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use. *JAMA* 1990;264:2737-2738.
41. Shionoiri H. Pharmacokinetic drug interactions with ACE inhibitors. *Clin Pharmacokinet* 1993;25:20-58.
42. Ray K, Dorman S, Watson R. Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction. *J Hum Hypertens* 1999;13:717-720.
43. Burnakis TG, Mioduch HJ. Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia. *Arch Intern Med* 1984;144:2371-2372.
44. Warren SE, O'Connor DT. Hyperkalemia resulting from captopril administration. *JAMA* 1980;244:2551-2552.
45. Grossman A, Eckland D, Price P, Edwards CR. Captopril: reversible renal failure with severe hyperkalaemia. *Lancet* 1980;1:712.
46. Burnakis TG. Captopril and increased serum potassium levels. *JAMA* 1984;252:1682-1683.
47. Rosa RM, Silva P, Young JB et al. Adrenergic modulation of extrarenal potassium disposal. *N Engl J Med* 1980;302:431-434.
48. Lundborg P. The effect of adrenergic blockade on potassium concentrations in different conditions. *Acta Med Scand Suppl* 1983;672:121-126.
49. Arthur S, Greenberg A. Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. *Clin Nephrol* 1990;33:269-271.
50. Rodriguez M, Solanki DL, Whang R. Refractory potassium repletion due to cisplatin-induced magnesium depletion. *Arch Intern Med* 1989;149:2592-2594.
51. Whang R, Whang DD, Ryan MP. Refractory potassium repletion: a consequence of magnesium deficiency. *Arch Intern Med* 1992;152:40-45.
52. Buckley JE, Clark VL, Meyer TJ, Pearlman NW. Hypomagnesemia after cisplatin combination chemotherapy. *Arch Intern Med* 1984;144:2347-2348.
53. Bianchetti MG, Kanaka C, Ridolfi-Luthy A et al. Chronic renal magnesium loss, hypocalciuria and mild hypokalaemic metabolic alkalosis after cisplatin. *Pediatr Nephrol* 1990;4:219-222.
54. Roe DA. Drug-Induced Nutritional Deficiencies. 2nd ed. Westport, Conn: Avi Publishing; 1985:159-160.
55. Werbach MR. Foundations of Nutritional Medicine. Tarzana, Calif: Third Line Press; 1997:223-224.
56. Thorn GW. Clinical considerations in the use of corticosteroids. *N Engl J Med* 1966;274:775-781.
57. Hormones, adrenal cortical steroids, glucocorticoids. In: Threlkeld DS, ed. Facts and Comparisons Drug Information. St Louis: Facts and Comparisons; April 1991:128b.
58. Stanbury RM, Graham EM. Systemic corticosteroid therapy — side effects and their management. *Br J Ophthalmol* 1998;82:704-708.
59. Kelly TM, Nelson DH. Sodium excretion and atrial natriuretic peptide levels during mineralocorticoid administration: a mechanism for the escape from hyperaldosteronism. *Endocr Res* 1987;13:363-383.
60. Krishna GG, Kapoor SC. Potassium depletion exacerbates essential hypertension. *Ann Intern Med* 1991;115:77-83.
61. Krishna GG, Kapoor SC. Potassium supplementation ameliorates mineralocorticoid-induced sodium retention. *Kidney Int* 1993;43:1097-1103.
62. Chacko M, Fordtran JS, Emmett M. Effect of mineralocorticoid activity on transtubular potassium gradient, urinary [K]/[Na] ratio, and fractional excretion of potassium. *Am J Kidney Dis* 1998;32:47-51.

Citations and Reference Literature: Potassium

63. Coruzzi P, Gualerzi M, Parati G et al. Potassium supplementation improves the natriuretic response to central volume expansion in primary aldosteronism. *Metabolism* 2003;52:1597-1600.
64. Newnham DM. Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing. *Drug Saf* 2001;24:1065-1080.
65. Wenzl HH, Fine KD, Santa Ana CA et al. Effect of fludrocortisone and spironolactone on sodium and potassium losses in secretory diarrhea. *Dig Dis Sci* 1997;42:119-128.
66. Imbriano LJ, Durham JH, Maesaka JK. Treating interdialytic hyperkalemia with fludrocortisone. *Semin Dial* 2003;16:5-7.
67. Olyaei AJ, de Mattos AM, Bennett WM. Immunosuppressant-induced nephropathy: pathophysiology, incidence and management. *Drug Saf* 1999;21:471-488.
68. You CW, Park YH, Lee ES et al. Effects of thyroxine on hyperkalemia and renal cortical Na⁺, K⁺-ATPase activity induced by cyclosporin A. *J Korean Med Sci* 2002;17:625-632.
69. Caliskan Y, Kalayoglu-Besisik S, Sargin D, Ecdar T. Cyclosporine-associated hyperkalemia: report of four allogeneic blood stem-cell transplant cases. *Transplantation* 2003;75:1069-1072.
70. Heering PJ, Kurschat C, Vo DT et al. Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression. *Clin Transplant* 2004;18:186-192.
71. Takami A, Asakura H, Takamatsu H et al. Isolated hyperkalemia associated with cyclosporine administration in allogeneic stem cell transplantation for renal cell carcinoma. *Int J Hematol* 2005;81:159-161.
72. Laine J, Holmberg C. Renal and adrenal mechanisms in cyclosporine-induced hyperkalaemia after renal transplantation. *Eur J Clin Invest* 1995;25:670-676.
73. Qvist E, Laine J, Ronnholm K et al. Graft function 5-7 years after renal transplantation in early childhood. *Transplantation* 1999;67:1043-1049.
74. Higgins R, Ramaiyan K, Dasgupta T et al. Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporine: further evidence for differences between cyclosporin and tacrolimus nephrotoxicities. *Nephrol Dial Transplant* 2004;19:444-450.
75. Stigant CE, Cohen J, Vivera M, Zaltzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. *Am J Kidney Dis* 2000;35:58-63.
76. Schmidt A, Gruber U, Bohmig G et al. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. *Nephrol Dial Transplant* 2001;16:1034-1037.
77. Singer M, Coluzzi F, O'Brien A, Clapp LH. Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. *Lancet* 2005;365:1873-1875.
78. Lown B, Black H, Moore FD. Digitalis, electrolytes and the surgical patient. *Am J Cardiol* 1960;6:309-337.
79. Smith TW, Willerson JT. Suicidal and accidental digoxin ingestion: report of five cases with serum digoxin level correlations. *Circulation* 1971;44:29-36.
80. Whang R, Oei TO, Watanabe A. Frequency of hypomagnesemia in hospitalized patients receiving digitalis. *Arch Intern Med* 1985;145:655-656.
81. Schmidt TA, Bundgaard H, Olesen HL et al. Digoxin affects potassium homeostasis during exercise in patients with heart failure. *Cardiovasc Res* 1995;29:506-511.
82. Martin BJ, Milligan K. Diuretic-associated hypomagnesemia in the elderly. *Arch Intern Med* 1987;147:1768-1771.
83. Kroenke K, Wood DR, Hanley JF. The value of serum magnesium determination in hypertensive patients receiving diuretics. *Arch Intern Med* 1987;147:1553-1556.
84. Zuccala G, Pedone C, Cocchi A et al. Older age and in-hospital development of hypokalemia from loop diuretics: results from a multicenter survey. GIFA Investigators, Multicenter Italian Pharmacoeconomic Study Group. *J Gerontol A Biol Sci Med Sci* 2000;55:M232-M238.
85. Franse LV, Pahor M, Di Bari M et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. *Hypertension* 2000;35:1025-1030.
86. Ruml LA, Pak CY. Effect of potassium magnesium citrate on thiazide-induced hypokalemia and magnesium loss. *Am J Kidney Dis* 1999;34:107-113.
87. Ruml LA, Gonzalez G, Taylor R et al. Effect of varying doses of potassium-magnesium citrate on thiazide-induced hypokalemia and magnesium loss. *Am J Ther* 1999;6:45-50.
88. Ritsema GH, Eilers G. Potassium supplements prevent serious hypokalaemia in colon cleansing. *Clin Radiol* 1994;49:874-876.
89. Moriarty KJ, Kelly MJ, Beetham R, Clark ML. Studies on the mechanism of action of dioctyl sodium sulphasuccinate in the human jejunum. *Gut* 1985;26:1008-1013.

Citations and Reference Literature: Potassium

90. Ewe K, Holker B. [The effect of a diphenolic laxative (bisacodyl) on water and electrolyte transport in the human colon] (author's translation). *Klin Wochenschr* 1974;52:827-833.
91. Farack UM, Gruber E, Loeschke K. The influence of bisacodyl and deacetyl-bisacodyl on mucus secretion, mucus synthesis and electrolyte movements in the rat colon in vivo. *Eur J Pharmacol* 1985;117:215-222.
92. Fleming BJ, Genuth SM, Gould AB, Kamionkowski MD. Laxative-induced hypokalemia, sodium depletion and hyperreninemia: effects of potassium and sodium replacement on the renin-angiotensin-aldosterone system. *Ann Intern Med* 1975;83:60-62.
93. Gastrointestinal drugs, laxatives. In: Threlkeld DS, ed. *Facts and Comparisons Drug Information*. St Louis: Facts and Comparisons; May 1991:319a.
94. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. *Am J Med* 2000;109:307-314.
95. Sica DA. Antihypertensive therapy and its effects on potassium homeostasis. *J Clin Hypertens (Greenwich)* 2006;8:67-73.
96. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001;345:861-869.
97. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. *Lancet* 2002;359:995-1003.
98. Toto R, Shultz P, Raij L et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group. *Hypertension* 1998;31:684-691.
99. Shahinfar S, Dickson TZ, Ahmed T et al. Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. *Kidney Int Suppl* 2002;64-67.
100. Schepkens H, Vanholder R, Billioud JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. *Am J Med* 2001;110:438-441.
101. Wrenger E, Muller R, Moesenthin M et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. *BMJ* 2003;327:147-149.
102. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. *Prescrire Int* 2005;14:180-186.
103. Kauffmann R, Orozco R, Venegas JC. [Severe hyperkalemia associated to the use of losartan and spironolactone: case report]. *Rev Med Chil* 2005;133:947-952.
104. Saito M, Takada M, Hirooka K et al. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. *J Clin Pharm Ther* 2005;30:603-610.
105. Fujii H, Nakahama H, Yoshihara F et al. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. *Kobe J Med Sci* 2005;51:1-6.
106. Miyahara Y, Miyazaki T, Tanaka Y et al. [A case of intraoperative hyperkalemia induced with administration of an angiotensin II receptor antagonist (AIIA) and intake of dried persimmons]. *Masui* 2004;53:543-546.
107. Bailie GR. Acute renal failure. In: Young LY, Kradjan WA, et al, eds. *Applied Therapeutics: the Clinical Use of Drugs*. 6th ed. Vancouver, W ash: Applied Therapeutics; 1995:29-33.
108. Poirier TI. Reversible renal failure associated with ibuprofen: case report and review of the literature. *Drug Intell Clin Pharm* 1984;18:27-32.
109. Whelton A, Stout RL, Spilman PS, Klassen DK. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure: a prospective, randomized, crossover comparison. *Ann Intern Med* 1990;112:568-576.
110. Po SS, Wang DW, Yang IC et al. Modulation of HERG potassium channels by extracellular magnesium and quinidine. *J Cardiovasc Pharmacol* 1999;33:181-185.
111. Roden DM, Iansmith DH. Effects of low potassium or magnesium concentrations on isolated cardiac tissue. *Am J Med* 1987;82:18-23.
112. Sadowski DC. Drug interactions with antacids: mechanisms and clinical significance. *Drug Saf* 1994;11:395-407.
113. Teplick JG, Teplick SK, Ominsky SH, Haskin ME. Esophagitis caused by oral medication. *Radiology* 1980;134:23-25.
114. Eng J, Sabanathan S. Drug-induced esophagitis. *Am J Gastroenterol* 1991;86:1127-1133.
115. Jackson PR, Ramsay LE, Wakefield V. Relative potency of spironolactone, triamterene and potassium chloride in thiazide-induced hypokalaemia. *Br J Clin Pharmacol* 1982;14:257-263.
116. Sawyer N, Gabriel R. Progressive hypokalaemia in elderly patients taking three thiazide potassium-sparing diuretic combinations for thirty-six months. *Postgrad Med J* 1988;64:434-437.
117. Schnaper HW, Freis ED, Friedman RG et al. Potassium restoration in hypertensive patients made hypokalemic by hydrochlorothiazide. *Arch Intern Med* 1989;149:2677-2681.

Citations and Reference Literature: Potassium

118. Stepan VM, Hammer HF, Krejs GJ. Hyperkalaemia and diarrhoea in a patient with surreptitious ingestion of potassium sparing diuretics. *Eur J Gastroenterol Hepatol* 1997;9:1001-1004.
119. Greenberg S, Reiser IW, Chou SY, Porush JG. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. *Ann Intern Med* 1993;119:291-295.
120. Velazquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. *Ann Intern Med* 1993;119:296-301.
121. Perazella MA. Trimethoprim-induced hyperkalaemia: clinical data, mechanism, prevention and management. *Drug Saf* 2000;22:227-236.
122. Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. *Ann Intern Med* 1996;124:316-320.
123. Alappan R, Buller GK, Perazella MA. Trimethoprim-sulfamethoxazole therapy in outpatients: is hyperkalemia a significant problem? *Am J Nephrol* 1999;19:389-394.
124. Choi MJ, Fernandez PC, Patnaik A et al. Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. *N Engl J Med* 1993;328:703-706.
125. Modest GA, Price B, Mascoli N. Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole. *Ann Intern Med* 1994;120:437; author reply 438.
126. Pennypacker LC, Mintzer J, Pitner J. Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole. *Ann Intern Med* 1994;120:437; author reply 438.
127. Canaday DH, Johnson JR. Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole. *Ann Intern Med* 1994;120:437-438.
128. Koc M, Bihorac A, Ozener CI et al. Severe hyperkalemia in two renal transplant recipients treated with standard dose of trimethoprim-sulfamethoxazole. *Am J Kidney Dis* 2000;36:E18.
129. Smith MJH, Smith PK. *The Salicylates: a Critical Bibliographic Review*. New York: Interscience; 1966.
130. Casis O, Espina L, Gallego M. Effects of amphetamine on calcium and potassium currents in rat heart. *J Cardiovasc Pharmacol* 2000;36:390-395.
131. Bowyer JF, Masserano JM, Weiner N. Inhibitory effects of amphetamine on potassium-stimulated release of [3H]dopamine from striatal slices and synaptosomes. *J Pharmacol Exp Ther* 1987;240:177-186.
132. Freed MI, Rastegar A, Bia MJ. Effects of calcium channel blockers on potassium homeostasis. *Yale J Biol Med* 1991;64:177-186.
133. Raab W. Cardiotoxic effects of emotional, socioeconomic, and environmental stresses. In: Bajusz E, Rona G, eds. *Myocardiology*. Vol I. Baltimore: University Park Press; 1970:707-713.
134. Mathe V, Kassay G, Tuske M. [Results of glucose tolerance tests and changes in inorganic serum phosphate and potassium levels in schizophrenic patients responding to treatment with psychotropic drugs]. *Int Pharmacopsychiatry* 1971;6:111-130.
135. Aunsholt NA. Prolonged Q-T interval and hypokalemia caused by haloperidol. *Acta Psychiatr Scand* 1989;79:411-412.
136. Blood modifiers, anticoagulants, heparin. In: Threlkeld DS, ed. *Facts and Comparisons Drug Information*. St. Louis: Facts and Comparisons; June 1997:87a-87f.
137. Matsumura M, Nakashima A, Tofuku Y. Electrolyte disorders following massive insulin overdose in a patient with type 2 diabetes. *Intern Med* 2000;39:55-57.
138. Kobler E, Nuesch HJ, Buhler H et al. [Drug-induced esophageal ulcers]. *Schweiz Med Wochenschr* 1979;109:1180-1182.
139. Mavromatis F. Tetracycline nephropathy: case report with renal biopsy. *JAMA* 1965;193:191-194.
140. Smith SR, Kendall MJ. Metabolic responses to beta 2 stimulants. *J R Coll Physicians Lond* 1984;18:190-194.
141. Cayton RM. Beta agonists and potassium. *Lancet* 1985;325:1395.
142. Haalboom JR, Deenstra M, Struyvenberg A. Hypokalaemia induced by inhalation of fenoterol. *Lancet* 1985;1:1125-1127.
143. Deacon SP. Salbutamol and hypokalaemia. *Lancet* 1976;1:1302.
144. Wager J, Fredholm BB, Lunell NO, Persson B. Development of tolerance to oral salbutamol in the third trimester of pregnancy: a study of circulatory and metabolic effects. *Br J Clin Pharmacol* 1981;12:489-495.
145. Smith SR, Gove I, Kendall MJ et al. Beta agonists and potassium. *Lancet* 1985;325:1394-1395.
146. Sydney MA. Ventricular arrhythmias associated with use of thioridazine hydrochloride in alcohol withdrawal. *BMJ* 1973;4:467.
147. Ryan MP. Interrelationships of magnesium and potassium homeostasis. *Miner Electrolyte Metab* 1993;19:290-295.
148. Dorup I, Skajaa K, Thybo NK. Oral magnesium supplementation restores the concentrations of magnesium, potassium and sodium-potassium pumps in skeletal muscle of patients receiving diuretic treatment. *J Intern Med* 1993;233:117-123.
149. Sansone RA. Complications of hazardous weight-loss methods. *Am Fam Physician* 1984;30:141-146.

Citations and Reference Literature: Potassium

150. Blumenthal M, Busse W, Goldberg A et al. The Complete German Commission E Monographs. Austin, Texas: American Botanical Council: Integrative Medicine Communications; 1998.

Reference Literature

- [No authors listed.] Drug evaluation annual. Vol 3. Milwaukee: American Medical Association; 1993.
- Adu D, Michael J, Turney J, McMaster P. Hyperkalemia in cyclosporine-treated renal allograft recipients. *Lancet* 1983;2(8346):370.
- Agarwal R, Afzalpurkar R, et al. Pathophysiology of potassium absorption and secretion by the human intestine. *Gastroenterology* 1994;107(2):548-571. (Review)
- Ahmed J, Weisberg LS. Hyperkalemia in dialysis patients. *Semin Dial* 2001;14(5):348-456. (Review)
- Akbarpour F, Afrasiabi A, Vaziri ND. Severe hyperkalemia caused by indomethacin and potassium supplementation. *South Med J* 1985;78(6):756-757.
- Aker S, Heering P, Kinne-Saffran E, et al. Different effects of cyclosporine a and FK506 on potassium transport systems in MDCK cells. *Exp Nephrol* 2001;9(5):332-340.
- Alpern RJ, Sakhae K. The clinical spectrum of chronic metabolic acidosis: homeostatic mechanisms produce significant morbidity. *Am J Kidney Dis* 1997;29:291-302.
- Ames BN. Micronutrient deficiencies: a major cause of DNA damage. *Ann N Y Acad Sci* 2000;889:87-106.
- Andersson B, Behnam-Motlagh P, Henriksson R, et al. Pharmacological modulation of lung cancer cells for potassium ion depletion. *Anticancer Res* 2005;25(4):2609-2616.
- Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure: DASH Collaborative Research Group. *N Engl J Med* 1997;336(16):1117-1124.
- Apstein C. Glucose-insulin-potassium for acute myocardial infarction: remarkable results from a new prospective, randomized trial. *Circulation* 1998;98:2223-2226.
- Apstein CS, Opie LH. Glucose-insulin-potassium (GIK) for acute myocardial infarction: a negative study with a positive value. *Cardiovasc Drugs Ther* 1999;13(3):185-189.
- Arnett T. Regulation of bone cell function by acid-base balance. *Proc Nutr Soc* 2002;62:511-520.
- Ascherio A, Rimm EB, Hernan MA, et al. Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. *Circulation* 1998;98(12):1198-1204.
- Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure: VAL-K Study Group. *Kidney Int* 2000;58:2084-2092.
- Bandyopadhyay S, Banerjee S. Severe hyperkalaemia with normal electrocardiogram. *Int J Clin Pract* 2001;55:486-487.
- Barden A, Beilin LJ, Vandongen R, et al. A double-blind placebo-controlled trial of the effects of short-term potassium supplementation on blood pressure and atrial natriuretic peptide in normotensive women. *Am J Hypertens* 1991;4(3 Pt 1):206-213.
- Barri YM, Wingo CS. The effects of potassium depletion and supplementation on blood pressure: a clinical review. *Am J Med Sci* 1997;314(1):37-40.
- Bauer JH, Reams G. Short- and long-term effects of calcium entry blockers on the kidney. *Am J Cardiol* 1987;59(2):66A-71A. (Review)
- Bazzano LA, He J, Ogden LG, et al. Dietary potassium intake and risk of stroke in US men and women: National Health and Nutrition Examination Survey I epidemiologic follow-up study. *Stroke* 2001;32(7):1473-1480.
- Berul CI, Morad M. Regulation of potassium channels by non-sedating antihistamines. *Circulation* 1995;91(8):2220-2225.
- Beyer FR, Dickinson HO, Nicolson DJ, et al. Combined calcium, magnesium and potassium supplementation for the management of primary hypertension in adults. *Cochrane Database Syst Rev* 2006;3:CD004805. (Review)
- Bowyer JF, Masserano JM, Weiner N. Inhibitory effects of amphetamine on potassium-stimulated release of [3H]dopamine from striatal slices and synaptosomes. *J Pharmacol Exp Ther* 1987;240(1):177-186.
- Bradberry SM, Vale JA. Disturbances of potassium homeostasis in poisoning. *J Toxicol Clin Toxicol* 1995;33(4):295-310. (Review)
- Brancati FL, Appel LJ, Seidler AJ, et al. Effect of potassium supplementation on blood pressure in African Americans on a low-potassium diet: a randomized, double-blind, placebo-controlled trial. *Arch Intern Med* 1996;156:61-67.
- Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. *Am J Med* 1999;107(6A):65S-70S.
- Brody T. Nutritional biochemistry. 2nd ed. San Diego: Academic Press; 1999. (Review)
- Bugge JF. Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs. *J Intern Med* 1996;240(4):249-251.
- Buist RA. Drug-nutrient interactions: an overview. *Int Clin Nutr Rev* 1984;4(3):114. (Review)

Citations and Reference Literature: Potassium

- Burgess E, Lewanczuk R, Bolli P, et al. Lifestyle modifications to prevent and control hypertension:6: recommendations on potassium, magnesium and calcium: Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. *CMAJ* 1999;160(9 Suppl):S35-S45.
- Bushinsky DA, Gavrillov K, Chabala JM, et al. Effect of metabolic acidosis on the potassium content of bone. *J Bone Miner Res* 1997;12:1664-1671.
- Cappuccio FP, MacGregor DA. Does potassium supplementation lower blood pressure? A meta-analysis of published trials. *J Hypertens* 1991;9:465-473. (Meta-analysis)
- Caudarella R, Vescini F, Buffa A, et al. Citrate and mineral metabolism: kidney stones and bone disease. *Front Biosci* 2003;8:1085-1106.
- Chakko SC, Frutche J, Gheorghiad M. Life-threatening hyperkalemia in severe heart failure. *Am Heart J* 1989;117(5):1083-1091.
- Chang HY, Hu YW, Yue CS, et al. Effect of potassium-enriched salt on cardiovascular mortality and medical expenses of elderly men. *Am J Clin Nutr* 2006;83(6):1289-1296.
- Chau L, Ratnaike RN. Drug-associated nutritional problems in older persons. *Rev Clin Gerontol* 2003;13:183-193. (Review)
- Choi CS, Lee FN, McDonough AA, et al. Independent regulation of in vivo insulin action on glucose versus K⁺ uptake by dietary fat and K⁺ content. *Diabetes* 2002;51:915-920.
- Clark BA, Brown RS. Potassium homeostasis and hyperkalemic syndromes. *Endocrinol Metab Clin North Am* 1995;24(3):573-591. (Review)
- Cohen L. Potassium replacement associated with the development of tetany in a patient with hypomagnesaemia. *Magn Res* 1993;6(1):43-45.
- Cox M. Potassium homeostasis. *Med Clin North Am* 1981;65(2):363-384. (Review)
- Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. *Nephrol Dial Transplant* 2003;18:1814-1819.
- Curhan GC, Willett WC, Rimm EB, et al. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. *N Engl J Med* 1993;328(12):833-838.
- Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. *Ann Intern Med* 1997;126(7):497-504.
- Davis BR, Oberman A, Blafox MD, et al. Lack of effectiveness of a low-sodium/high-potassium diet in reducing antihypertensive medication requirements in overweight persons with mild hypertension:TAIM Research Group: Trial of Antihypertensive Interventions and Management. *Am J Hypertens* 1994;7:926-932.
- Demigné C, Sabboh H, Puel C, et al. Organic anions and potassium salts in nutrition and metabolism. *Nutr Res Rev* 2004;17(2):249-258.
- Demigné C, Sabboh H, Révész C, et al. Protective effects of high dietary potassium: nutritional and metabolic aspects. *J Nutr* 2004;134(11):2903-2906. (Review)
- Deutsch C. Potassium channel ontogeny. *Annu Rev Physiol* 2002;64:19-46. (Review)
- Dickey RA, Janick JJ. Lifestyle modifications in the prevention and treatment of hypertension. *Endocr Pract* 2001;7(5):392-399. (Review)
- Dickinson HO, Nicolson DJ, Campbell F, et al. Potassium supplementation for the management of primary hypertension in adults. *Cochrane Database Syst Rev* 2006;3:CD004641. (Review)
- Djurhuus MS, Vaag A, Klitgaard NA. Muscle sodium, potassium, and [(3H)]ouabain binding in identical twins, discordant for type 2 diabetes. *J Clin Endocrinol Metab* 2001;86:859-866.
- Domrongkitchaiporn S, Stithantrakul W, Kochakarn W. Causes of hypocitraturia in recurrent calcium stone formers: focusing on urinary potassium excretion. *Am J Kidney Dis* 2006;48(4):546-554.
- Dorph S, Oigaard A. [Effect of triamterene on serum potassium and serum creatinine in long-term treatment with thiazides.] *Nord Med* 1968;79(16):516-518. [Danish]
- Dos Santos P, Kowaltowski AJ, Laclau MN, et al. Mechanisms by which opening the mitochondrial ATP- sensitive K⁽⁺⁾ channel protects the ischemic heart. *Am J Physiol Heart Circ Physiol* 2002;283(1):H284-295.
- Dyckner T, Wester PO. Ventricular extrasystoles and intracellular electrolytes before and after potassium and magnesium infusions in patients on diuretic treatment. *Am Heart J* 1979;97(1):12-18.
- Dyckner T, Wester PO. Ventricular extrasystoles and intracellular electrolytes in hypokalemic patients before and after correction of the hypokalemia. *Acta Med Scand* 1978;204(5):375-379.
- Elisaf M, Milionis H, Siamopoulos KC. Hypomagnesemic hypokalemia and hypocalcemia: clinical and laboratory characteristics. *Miner Electrolyte Metab* 1997;23(2):105-112.
- Epstein W. The roles and regulation of potassium in bacteria. *Prog Nucleic Acid Res Mol Biol* 2003;75:293-320.
- Evans KJ, Greenberg A. Hyperkalemia: a review. *J Intensive Care Med* 2005;20(5):272-290. (Review)

Citations and Reference Literature: Potassium

- Evans KJ, Reddan DN, Szczech LA. Nondialytic management of hyperkalemia and pulmonary edema among end-stage renal disease patients: an evaluation of the evidence. *Semin Dial* 2004;17(1):22-29. (Review)
- Ewe K. Influence of diphenolic laxatives on water and electrolyte permeation in man. Monograph 1977:420-426.
- Fang J, Madhavan S, Alderman MH. Dietary potassium intake and stroke mortality. *Stroke* 2000;31(7):1532-1537.
- Férraille E, Mordasini D, Gonin S, et al. Mechanism of control of Na,K-ATPase in principal cells of the mammalian collecting duct. *Ann N Y Acad Sci* 2003;986:1-9.
- Floris-Moore MA, Amodio-Groton MI, Catalano MT. Adverse reactions to trimethoprim/sulfamethoxazole in AIDS. *Ann Pharmacother* 2003;37(12):1810-1813.
- Flynn JT, Bunchman TE, Sherbotie JR. Indications, results, and complications of tacrolimus conversion in pediatric renal transplantation. *Pediatr Transplant* 2001;5(6):439-446.
- Follmer CH, Colatsky TJ. Block of delayed rectifier potassium current, IK, by flecainide and E-4031 in cat ventricular myocytes. *Circulation* 1990;82(1):289-293.
- Food and Nutrition Board, Institute of Medicine. Potassium: dietary reference intakes for water, potassium, sodium, chloride, and sulfate. Washington, DC: National Academies Press; 2004:173-246.
- Fotherby MD, Potter JF. Potassium supplementation reduces clinic and ambulatory blood pressure in elderly hypertensive patients. *J Hypertens* 1992;10:1403-1408.
- Frassetto LA, Morris RC, Sellmeyer DE, et al. Diet, evolution and aging: the physiopathologic effects of post-agricultural inversion of the potassium-to-sodium and base-to-chloride ratios in the human diet. *Eur J Nutr* 2001;40:200-213.
- Garland HO, Phipps DJ, Harpur ES. Gentamicin-induced hypercalciuria in the rat: assessment of nephron site involved. *J Pharmacol Exp Ther* 1992;263(1):293-297.
- Garlid KD, Dos Santos P, Xie ZJ, et al. Mitochondrial potassium transport: the role of the mitochondrial ATP-sensitive K(+) channel in cardiac function and cardioprotection. *Biochim Biophys Acta* 2003;1606(1-3):1-21. (Review)
- Garlid KD, Paucek P. Mitochondrial potassium transport: the K(+) cycle. *Biochim Biophys Acta* 2003;1606(1-3):23-41. (Review)
- Gennari FJ. Disorders of potassium homeostasis: hypokalemia and hyperkalemia. *Crit Care Clin* 2002;18(2):273-288,vi. (Review)
- Gennari FJ. Hypokalemia. *N Engl J Med* 1998;339(7):451-458.
- Giebisch G. A trail of research on potassium. *Kidney Int* 2002;62:1498-1512.
- Giebisch G. Renal potassium transport: mechanisms and regulation. *Am J Physiol* 1998;274:F817-F833.
- Gilliland FD, Berhane KT, Li YF, et al. Dietary magnesium, potassium, sodium, and children's lung function. *Am J Epidemiol* 2002;155(2):125-131.
- Goldszer RC, Coodley EL, Rosner MJ, et al. Hyperkalemia associated with indomethacin. *Arch Intern Med* 1981;141(6):802-804.
- Good CB, McDermott L, McCloskey B. Diet and serum potassium in patients on ACE inhibitors. *JAMA* 1995;274(7):538. (Letter)
- Gosmanov AR, Thomason DB. Insulin and isoproterenol differentially regulate mitogen-activated protein kinase-dependent Na⁺-K⁺-2Cl⁻ cotransporter activity in skeletal muscle. *Diabetes* 2002;51:615-623.
- Greenberg A. Hyperkalemia: treatment options. *Semin Nephrol* 1998;18(1):46-57. (Review)
- Grobbée DE, Hofman A, Roelandt JT, et al. Sodium restriction and potassium supplementation in young people with mildly elevated blood pressure. *J Hypertens* 1987;5:115-119.
- Gu D, He J, Wu X, et al. Effect of potassium supplementation on blood pressure in Chinese: a randomized, placebo-controlled trial. *J Hypertens* 2001;19(7):1325-1331.
- Güven M, Onaran I, Ulutin T, et al. Effect of acute hyperglycemia on potassium (86Rb⁺) permeability and plasma lipid peroxidation in subjects with normal glucose tolerance. *J Endocrinol Invest* 2001;24:231-235.
- Hajjar IM, Grim CE, George V, et al. Impact of diet on blood pressure and age-related changes in blood pressure in the US population: analysis of NHANES III. *Arch Intern Med* 2001;161(4):589-593.
- Harrington M, Cashman KD. High salt intake appears to increase bone resorption in postmenopausal women but high potassium intake ameliorates this adverse effect. *Nutr Rev* 2003;61:179-183.
- Hartmann RC, Audire JV, Jackson DP. Hyperkalemia due to release of potassium from platelets during coagulation. *J Clin Invest* 1958;37:699.
- Heering P, Grabensee B. Influence of ciclosporin A on renal tubular function after kidney transplantation. *Nephron* 1991;59(1):66-70.
- Hendler SS, Rorvik DR, eds. PDR for nutritional supplements. Montvale, NJ: Medical Economics Company, Inc; 2001. (Review)
- Herman E, Rado J. Fatal hyperkalemic paralysis associated with spironalactone: observation on a patient with severe renal disease and refractory edema. *Arch Neurol* 1966;15(1):74-77.
- Herman E, Rado J. [Hyperkalemia with fatal paralysis in a diabetic patient treated with aldactone.] *Orv Hetil* 1967;108(2):74-76. [Hungarian]

Citations and Reference Literature: Potassium

- Hermansen K. Diet, blood pressure and hypertension. *Br J Nutr* 2000;83(Suppl 1):S113-119.
- Higgins R, Ramaiyan K, Dasgupta T, et al. Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin: further evidence for differences between cyclosporin and tacrolimus nephrotoxicities. *Nephrol Dial Transplant* 2004;19(2):444-450.
- Hijazi N, Abalkhail B, Seaton A. Diet and childhood asthma in a society in transition: a study in urban and rural Saudi Arabia. *Thorax* 2000;55:775-779.
- Holbrook JT, Cottrell SL, Smith JC Jr. Correlations of changes in dietary potassium and sodium with blood pressure during a one-year study. *Am J Clin Nutr* 1984;40(6 Suppl):1390-1392.
- Holbrook JT, Patterson KY, Bodner JE, et al. Sodium and potassium intake and balance in adults consuming self-selected diets. *Am J Clin Nutr* 1984;40(4):786-793.
- Hollander-Rodriguez JC, Calvert JF Jr. Hyperkalemia. *Am Fam Physician* 2006;73(2):283-290. (Review)
- Holt GA. Food and drug interactions. Chicago: Precept Press;1998.
- Howes LG. Which drugs affect potassium? *Drug Saf* 1995;12(4):240-244.
- Hylander B. Survival of extreme hyperkalemia. *Acta Med Scand* 1987;221(1):121-123.
- Iso H, Stampfer MJ, Manson JE, et al. Prospective study of calcium, potassium, and magnesium intake and risk of stroke in women. *Stroke* 1999;30(9):1772-1779.
- Joint National Committee. Sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. *Arch Int Med* 1997;157:2413-2446.
- Jones G, Riley MD, Whiting S. Association between urinary potassium, urinary sodium, current diet, and bone density in prepubertal children. *Am J Clin Nutr* 2001;73:839-844.
- Joshi KJ, Ascherio A, Manson JE, et al. Fruit and vegetable intake in relation to risk of ischemic stroke. *JAMA* 1999;282(13):1233-1239.
- Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. *JAMA* 2003;289:1652-1658.
- Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. *N Engl J Med* 2004;351:543-551.
- Kang D, et al. Lemonade-based dietary manipulation in patients with hypocitraturic nephrolithiasis. Abstract 1038. American Urological Association 101st Annual Meeting. Atlanta, May 25, 2006.
- Kendler BS. Recent nutritional approaches to the prevention and therapy of cardiovascular disease. *Prog Cardiovasc Nurs* 1997;12(3):3-23.
- Kerr DJ, McAlpine LG, Dagg JH. Pseudohyperkalaemia. *BMJ* 1985;291:890-891.
- Khaw KT, Thom S. Randomized double-blind crossover trial of potassium on blood pressure in normal subjects. *Lancet* 1982;2:1127-1129.
- Kim HC, Hwang EA, Han SY, et al. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center. *Transplant Proc* 2004;36(7):2082-2083.
- Kosek JC, Mazze RI, Cousins MJ. Nephrotoxicity of gentamicin. *Lab Invest* 1974;30(1):48-57.
- Krauss RM, Eckel RH, Howard B, et al. AHA dietary guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. *Circulation* 2000;102:2284-2299.
- Lemann J Jr, Pleuss JA, Gray RW. Potassium causes calcium retention in healthy adults. *J Nutr* 1993;123(9):1623-1626.
- Lenz T, Becker B, Bergner R. [Potassium in renal disease.] *Med Klin (Munich)* 2004;99(7):355-361. [German]
- Liu S, Manson JE, Lee IM, et al. Fruit and vegetable intake and risk of cardiovascular disease: the Women's Health Study. *Am J Clin Nutr* 2000;72(4):922-928.
- Lotz M, Zisman E, Bartter FC. Evidence for a phosphorus-depletion syndrome in man. *N Engl J Med* 1968;278:409.
- MacCarthy EP, Frost GW, Strokes GS. Indomethacin-induced hyperkalaemia. *Med J Aust* 1979;1(12):550.
- Mactier RA, Khanna R. Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone. *South Med J* 1988;81(6):799-801.
- Mandal AK. Hypokalemia and hyperkalemia. *Med Clin North Am* 1997;81(3):611-639.
- Marinella MA. Trimethoprim-induced hyperkalemia: an analysis of reported cases. *Gerontology* 1999;45(4):209-212.
- Markovich D, Wang H, Puttaparthi K, et al. Chronic K depletion inhibits renal brush border membrane Na/sulfate cotransport. *Kidney Int* 1999;55:244-251.
- Marz R. Medical nutrition from Marz. 2nded. Portland, OR: Omni Press; 1997.

Citations and Reference Literature: Potassium

- McCarron DA, Reussner ME. Are low intakes of calcium and potassium important causes of cardiovascular disease? *Am J Hypertens* 2001;14:206S-212S.
- Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? *J Am Coll Cardiol* 2004;43(2):155-161. (Review)
- McDonough AA, Thompson CB, Youn JH. Skeletal muscle regulates extracellular potassium. *Am J Physiol* 2002;282:F967-F974.
- McKenna MJ, Harmer AR, Fraser SF, et al. Effects of training on potassium, calcium and hydrogen ion regulation in skeletal muscle and blood during exercise. *Acta Physiol Scand* 1996;156(3):335-346. (Review)
- McLean, R. Magnesium and its therapeutic uses: a review. *Am J Med* 1994;96(1):63-76. (Review)
- Meneton P, Loffing J, Warnock DG. Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule. *Am J Physiol* 2004;287:F593-F601.
- Meneton P, Schultheis PJ, Greeb J, et al. Increased sensitivity to K⁺ deprivation in colonic H,K-ATPase-deficient mice. *J Clin Investig* 1998;101:536-542.
- Mironova GD, Negoda AE, Marinov BS, et al. Functional distinctions between the mitochondrial ATP-dependent K⁺ channel (mitoKATP) and its inward rectifier subunit (mitoKIR). *J Biol Chem* 2004;279(31):32562-32568.
- Miyachi Y, Niwa Y. Effects of potassium iodide, colchicine and dapsone on the generation of polymorphonuclear leukocyte-derived oxygen intermediates. *Br J Dermatol* 1982;107(2):209-214.
- Montie T, Patamasucon P. Aminoglycosides: the complex problem of antibiotic mechanisms and clinical applications. *Eur J Clin Microbiol Infect Dis* 1995;14:85-87. (Editorial)
- Morganti A. Should a diuretic always be the first choice in patients with essential hypertension? The case for no. *J Am Soc Nephrol* 2005;16(3 Suppl 1):S70-S73.
- Morita H, Fujiki N, Miyahara T, et al. Hepatoportal bumetanide-sensitive K⁺-sensor mechanism controls urinary K⁺ excretion. *Am J Physiol* 2000;278:R1134-R1139.
- Morris RC, Frassetto LA, Schmidlin O, et al. Expression of osteoporosis as determined by diet-disordered electrolyte and acid-base metabolism. In: Burkhardt P, Dawson-Hughes B, Heaney R, eds. *Nutritional aspects of osteoporosis*. San Diego: Academic Press; 2001:357-378.
- Morris RC, Jr, Schmidlin O, Tanaka M, et al. Differing effects of supplemental KCl and KHCO₃: pathophysiological and clinical implications. *Semin Nephrol* 1999;19(5):487-493.
- Nakada S, et al. Medical management of calcium oxalate stone formers with lemonade results in therapeutic urinary citrate and higher urine volumes than those on potassium citrate. Abstract 1537. American Urological Association 101st Annual Meeting. Atlanta, May 25, 2006.
- New SA. Intake of fruit and vegetables: implications for bone health. *Proc Nutr Soc* 2003;62:859-899.
- New SA, Bolton-Smith C, Grubb DA, et al. Nutritional influences on bone mineral density: a cross-sectional study in premenopausal women. *Am J Clin Nutr* 1997;65(6):1831-1839.
- New SA, Robins SP, Campbell MK, et al. Dietary influences on bone mass and bone metabolism: further evidence of a positive link between fruit and vegetable consumption and bone health? *Am J Clin Nutr* 2000;71(1):142-151.
- Nielsen H, Landbo K. [Hypokalemia, myopathy with myoglobinuria after prolonged ingestion of licorice.] *Ugeskr Laeger* 1970;132(38):1778-1780. [Danish]
- Nieves JW. Osteoporosis: the role of micronutrients. *Am J Clin Nutr* 2005;81(5):1232S-1239S. (Review)
- Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. *Am J Hypertens* 2003;16:925-930.
- Olukoga A, Donaldson D. Licorice and its health implications. *J R Soc Health* 2000;120(2):83-89.
- Overlack A, Maus B, Ruppert M, et al. Potassium citrate versus potassium chloride in essential hypertension: effects on hemodynamic, hormonal and metabolic parameters. *Dtsch Med Wochenschr* 1995;120:631-635. [German; English abstract]
- Pajor AM. Sodium-coupled transporters for Krebs cycle intermediates. *Annu Rev Physiol* 1999;61:663-682.
- Pamnati MB, Bryant HJ, Clough DL, et al. Increased dietary potassium and magnesium attenuate experimental volume dependent hypertension possibly through endogenous sodium-potassium pump inhibitor. *Clin Exp Hypertens* 2003;25:103-115.
- Patki PS, Singh J, Gokhale SV, et al. Efficacy of potassium and magnesium in essential hypertension: a double-blind, placebo controlled, crossover study. *BMJ* 1990;301(6751):521-523.
- Paucek P, Jaburek M. Kinetics and ion specificity of Na⁽⁺⁾/Ca⁽²⁺⁾ exchange mediated by the reconstituted beef heart mitochondrial Na⁽⁺⁾/Ca⁽²⁺⁾ antiporter. *Biochim Biophys Acta* 2004;1659(1):83-91.
- Perazella MA. Hyperkalemia in the elderly: a group at high risk. *Conn Med* 1996;60(4):195-198.

Citations and Reference Literature: Potassium

- Perazella MA, Mahnensmith RL. Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis. *J Gen Intern Med* 1997;12(10):646-656. (Review)
- Perazella MA, Mahnensmith RL. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. *Clin Nephrol* 1996;46(3):187-192. (Review)
- Perlmutter EP, Sweeney D, Herskovits G, et al. Case report: severe hyperkalemia in a geriatric patient receiving standard doses of trimethoprim-sulfamethoxazole. *Am J Med Sci* 1996;311(2):84-85.
- Peterson LN. Potassium in nutrition. In: O'Dell BL, Sunde RA, eds. *Handbook of nutritionally essential minerals*. New York: Marcel Dekker, Inc; 1997:153-183.
- Preston RA, Hirsh MJ, Oster JR, et al. University of Miami Division of Clinical Pharmacology therapeutic rounds: drug-induced hyperkalemia. *Am J Ther* 1998;5(2):125-132.
- Prevot A, Martini S, Guignard JP. In utero exposure to immunosuppressive drugs. *Biol Neonate* 2002;81(2):73-81. (Review)
- Pronsky Z. Powers and Moore's food-medications interactions. 9th ed. Pottstown, PA: Food-Medication Interactions; 1991. (Review)
- Rabinowitz L, Sarason RL, Yamauchi H, et al. Time course of adaptation to altered K intake in rats and sheep. *Am J Physiol* 1984;247:F607-F617.
- Rabinowitz L. Homeostatic regulation of potassium excretion. *J Hypertens* 1989;7:433-442.
- Ray K, Dorman S, Watson R. Severe hyperkalemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction. *J Hum Hypertens* 1999;13(10):717-720.
- Reif S, Klein I, Lubin F, et al. Pre-illness dietary factors in inflammatory bowel disease. *Gut* 1997;40:754-760.
- Remer T, Manz F. Potential renal acid load of foods and its influence on urine pH. *J Am Diet Assoc* 1995;95:791-797.
- Remer T. Influence of diet on acid-base balance. *Semin Dial* 2000;13:221-226.
- Reiser IW, Chou SY, Brown MI, et al. Reversal of trimethoprim-induced antidiuresis. *Kidney Int* 1996;50(6):2063-2069.
- Resnick LM. Cellular ions in hypertension, insulin resistance, obesity and diabetes: an unifying theme. *J Am Soc Nephrol* 1992;3:S78-S85.
- Robinson C, Weigly E. *Basic nutrition and diet therapy*. New York: MacMillan; 1984. (Review)
- Roe DA. *Diet and drug interactions*. New York: Van Nostrand Reinhold; 1989. (Review)
- Roe DA. *Drug-induced nutritional deficiencies*. 2nd ed. Westport, CT: Avi Publishing; 1985. (Review)
- Roe DA. Risk factors in drug-induced nutritional deficiencies. In: Roe DA, Campbell T, eds. *Drugs and nutrients: the interactive effects*. New York: Marcel Decker; 1984:505-523. (Review)
- Rosenkranz RP, McClelland DL, Roszkowski AP. Effects of nicardipine, nifedipine, verapamil, and diltiazem on urine volume, sodium and potassium excretion and plasma aldosterone levels in the rat. *Proc West Pharmacol Soc* 1984;27:67-72.
- Ryan MP. Interrelationships of magnesium and potassium homeostasis. *Miner Electrolyte Metab* 1993;19(4-5):290-295.
- Sabboh H, Besson C, Tressol JC, et al. Organic potassium salts or fibers effects on mineral balance and digestive fermentations in rats adapted to an acidogenic diet. *Eur J Nutr* 2006;45(6):342-348.
- Sacks FM, Brown LE, Appel L, et al. Combinations of potassium, calcium, and magnesium supplements in hypertension. *Hypertension* 1995;26(6 Pt 1):950-956.
- Sacks FM, Obarzanek E, Windhauser MM, et al. Rationale and design of the Dietary Approaches to Stop Hypertension trial (DASH): a multicenter controlled-feeding study of dietary patterns to lower blood pressure. *Ann Epidemiol* 1995;5(2):108-118.
- Sacks FM, Willett WC, Smith A, et al. Effect on blood pressure of potassium, calcium, and magnesium in women with low habitual intake. *Hypertension* 1998;31(1):131-138.
- Saito N, Kuchiba A. The changes of magnesium under high salt diets and by administration of antihypertensive diuretics. *Magnes Bull* 1987;9:53.
- Salem MM, Rosa RM, Battle DC. Extrarenal potassium tolerance in chronic renal failure: implications for the treatment of acute hyperkalemia. *Am J Kidney Dis* 1991;18(4):421-440. (Review)
- Schaefer M, Link J, Hannemann L, et al. Excessive hypokalemia and hyperkalemia following head injury. *Intensive Care Med* 1995;21(3):235-237.
- Schaefer TJ, Wolford RW. Disorders of potassium. *Emerg Med Clin North Am* 2005;23(3):723-747, viii-ix. (Review)
- Schlanger LE, Kleyman TR, Ling BN. K(+)-sparing diuretic actions of trimethoprim: inhibition of Na+ channels in A6 distal nephron cells. *Kidney Int* 1994;45:1070-1076.
- Schmidt A, Gruber U, Bohmig G, et al. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. *Nephrol Dial Transplant* 2001;16(5):1034-1037.
- Schwartz AB. Potassium-related cardiac arrhythmias and their treatment. *Angiology*. 1978;29(3):194-205.

Citations and Reference Literature: Potassium

- Seah TG, Lew TW, Chin NM. A case of pseudohyperkalemia and thrombocytosis. *Ann Acad Med Singapore* 1998;27:442-443.
- Sebastian A, Harris ST, Ottaway JH, et al. Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium bicarbonate. *N Engl J Med* 1994;330(25):1776-1781.
- Sheng H-W. Sodium, chloride and potassium. In: Stipanuk M, ed. *Biochemical and physiological aspects of human nutrition*. Philadelphia: WB Saunders; 2000:686-710.
- Sica DA. Antihypertensive therapy and its effects on potassium homeostasis. *J Clin Hypertens (Greenwich)* 2006;8(1):67-73. (Review)
- Sica DA. Eplerenone and serum potassium change: relationship to renal function. *Am J Hypertens* 2003;16(Suppl 1):A100.
- Sica DA, Hess M. Pharmacotherapy in congestive heart failure: aldosterone receptor antagonism: interface with hyperkalemia in heart failure. *Congest Heart Fail* 2004;10:259-264.
- Singer GG, Brenner BM. Fluid and electrolyte disturbances. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, eds. *Harrison's principles of internal medicine*. 14th ed. New York: McGraw-Hill; 1998:269.
- Singh RB, Singh NK, Niaz MA, et al. Effect of treatment with magnesium and potassium on mortality and reinfarction rate of patients with suspected acute myocardial infarction. *Int J Clin Pharmacol Ther* 1996;34:219-225.
- Skinner SL. A cause of erroneous potassium levels. *Lancet* 1961;i:478-480.
- Sugarman A, Kahn T. Calcium channel blockers enhance extrarenal potassium disposal in the rat. *Am J Physiol* 1986;250(4 Pt 2):F695-701.
- Suter PM. Potassium and hypertension. *Nutr Rev* 1998;56:151-133. (Review)
- Sweeney G, Klip A. Mechanisms and consequences of Na⁺,K⁺-pump regulation by insulin and leptin. *Cell Mol Biol* 2001;47:363-372.
- Tamirisa KP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. *Am Heart J* 2004;148:971-978.
- Tan SY, Burton M. Hyporeninemic hypoaldosteronism: an overlooked cause of hyperkalemia. *Arch Intern Med* 1981;141(1):30-33.
- Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. *J Heart Lung Transplant* 1999;18(4):336-345.
- Textor SC, Bravo EL, Fouad FM, Tarazi RC. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. *Am J Med* 1982;73(5):719-725.
- Threlkeld DS, ed. Anti-infectives, tetracyclines. In: *Facts and comparisons drug information*. St Louis: Facts and Comparisons;1989.
- Threlkeld DS, ed. Diuretics and cardiovasculars, antihyperlipidemic agents, HMG-CoA reductase inhibitors. In: *Facts and comparisons drug information*. St Louis: Facts and Comparisons;1998.
- Threlkeld DS, ed. Hormones, adrenal cortical steroids, glucocorticoids. In: *Facts and comparisons drug information*. St Louis: Facts and Comparisons;1991.
- Threlkeld DS, ed. Respiratory drugs, bronchodilators, sympathomimetics. In *Facts and comparisons drug information*. St Louis: Facts and Comparisons;1994:174a-175.
- Toffaletti J. Electrolytes, divalent cations, and blood gases (magnesium). *Anal Chem* 1991;63(12):192R-194R.
- Trinchieri A, Zanetti G, Curro A, et al. Effect of potential renal acid load of foods on calcium metabolism of renal calcium stone formers. *Eur Urol* 2001;39(Suppl 2):33-36.
- Trovato A, Nuhlicek DN, Midtling JE. Drug-nutrient interactions. *Am Fam Physician* 1991;44(5):1651-1658.(Review)
- Tsuruoka S, Schwartz GJ, Ioka T, et al. Citrate reverses cyclosporin A-induced metabolic acidosis and bone resorption in rats. *Am J Nephrol* 2005;25(3):233-239.
- Tucker KL, Hannan MT, Chen H, et al. Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. *Am J Clin Nutr* 1999;69(4):727-736.
- USDA. *Composition of foods: USDA handbook #8*. Washington, DC:ARS, USDA;1976-1986.
- Wang DW, Sato T, Arita M. Voltage dependent inhibition of ATP sensitive potassium channels by flecainide in guinea pig ventricular cells. *Cardiovasc Res* 1995;29(4):520-525.
- Wasan KM, Wong JC, Corr T, et al. Role of plasma lipids and lipoproteins in predicting amphotericin B-induced nephrotoxicity in pediatric oncology patients. *Cancer Chemother Pharmacol* 2006;57(1):120-124.
- Weisberg LS, Szerlip HM, Cox M. Disorders of potassium homeostasis in critically ill patients. *Crit Care Clin* 1987;3(4):835-854. (Review)
- Werbach MR. *Foundations of nutritional medicine*. Tarzana, CA: Third Line Press;1997. (Review)
- Whang R, Whang DD, Ryan MP. Refractory potassium repletion: a consequence of magnesium deficiency. *Arch Intern Med* 1992;152:40-45. (Review)
- Whelton PK, He J. Potassium in preventing and treating high blood pressure. *Semin Nephrol* 1999;19(5):494-499. (Meta-analysis)

Citations and Reference Literature: Potassium

- Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure: meta-analysis of randomized controlled clinical trials. *JAMA* 1997;277(20):1624-1632.
- Witt JM, Koo JM, Danielson BD. Effect of standard-dose trimethoprim/sulfamethoxazole on the serum potassium concentration in elderly men. *Ann Pharmacother* 1996;30(4):347-350.
- Wright LF, DuVal JW Jr. Renal injury associated with laxative abuse. *South Med J* 1987;80(10):1304-1306.
- Yang LE, Leong PKK, Guzman JP, et al. Modest K⁺ restriction provokes insulin resistance of cellular K⁺ uptake without decrease in plasma K⁺. *Ann N Y Acad Sci* 2003;986:625-627.
- Yeh JK, Aloia JF, Semla HM. Interrelation of cortisone and 1,25 dihydroxycholecalciferol on intestinal calcium and phosphate absorption. *Calcif Tissue Int* 1984;36(5):608-614.
- Young DB, Lin H, McCabe RD. Potassium's cardiovascular protective mechanisms. *Am J Physiol* 1995;268(4 Part 2):R825-R837.
- Young DB, Ma G. Vascular protective effects of potassium. *Semin Nephrol* 1999;19:477-486.
- Young IS, Goh EM, McKillop UH, et al. Magnesium status and digoxin toxicity. *Br J Clin Pharmacol* 1991;32(6):717-721.
- Zaman R, Wilkins MR, Kendall MJ, et al. The effect of food and alcohol on the pharmacokinetics of acebutolol and its metabolite, diacetolol. *Biopharm Drug Dispos* 1984;5:91-95.
- Zanabli AR, Yango A, Dworkin L. Incidence of hyperkalemia in high risk patients during treatment with an angiotensin converting enzyme inhibitor (Lisinopril) versus an angiotensin II receptor blocker (Losartan). *SDJ Med* 2004;57(6):227-231.
- Zull DN. Disorders of potassium metabolism. *Emerg Med Clin North Am* 1989;7(4):771-94. (Review)